SCHEMBL6479199

SCHEMBL6479199

NC(=O)Cc1cccc(Nc2ncnc(-n3c(N)nc4ccccc43)n2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 12/20 0.52
MTOR P42345 12/20 0.52
AURKA O14965 2/20 0.46
PIK3CD O00329 4/20 0.45
PIK3CB P42338 4/20 0.45
PIK3CG P48736 4/20 0.45
KDR P35968 3/20 0.45
RAF1 P04049 1/20 0.45
BRAF P15056 1/20 0.45
TGFBR2 P37173 1/20 0.45
CSNK1D P48730 1/20 0.45
SCN9A Q15858 4/20 0.44
LCK P06239 2/20 0.43
MAPK14 Q16539 2/20 0.43
CHEK1 O14757 1/20 0.42
MAP3K7 O43318 1/20 0.42
NUAK1 O60285 1/20 0.42
JAK2 O60674 1/20 0.42
BMX P51813 1/20 0.42
NEK2 P51955 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6485821 0.89 PIK3CA (0.52) PIK3CAMTORAURKAPIK3CDPIK3CB
SCHEMBL14214732 0.86 SCN9A (0.59) PIK3CAMTORPIK3CDPIK3CBPIK3CG
SCHEMBL14380903 0.85 AURKA (0.52) PIK3CAMTORAURKAKDRLCK
SCHEMBL6479848 0.84 PIK3CA (0.54) PIK3CAMTORPIK3CDPIK3CBPIK3CG
SCHEMBL14214728 0.80 MKNK1 (0.53) PIK3CAMTORAURKAPIK3CDPIK3CB
SCHEMBL6479012 0.79 PIK3CA (0.47) PIK3CAMTORPIK3CDPIK3CBPIK3CG
SCHEMBL6492733 0.78 PIK3CA (0.50) PIK3CAMTORPIK3CDPIK3CBPIK3CG
SCHEMBL3244139 0.76 PIK3CA (0.55) PIK3CAMTORAURKAPIK3CDPIK3CB
SCHEMBL6479037 0.75 AURKA (0.54) AURKASCN9ACHEK1MAP3K7NUAK1
SCHEMBL14214627 0.75 AURKA (0.48) PIK3CAMTORAURKAKDRLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6864255-B2 Substituted triazinyl amide derivatives and methods of use AMGEN INC. (US) 2005-03-08 US disclosed
US-20030087908-A1 Substituted triazinyl amide derivatives and methods of use AMGEN INC. 2003-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087908-A1 Substituted triazinyl amide derivatives and methods of use FLT4, FLT1, VEGFA PIK3CA 475/4885MTOR 1843/4885AURKA 2141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.